Titre : Transgènes

Transgènes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Eye Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Transgènes : Questions médicales les plus fréquentes", "headline": "Transgènes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Transgènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-06", "dateModified": "2025-03-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Transgènes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Gènes", "url": "https://questionsmedicales.fr/mesh/D005796", "about": { "@type": "MedicalCondition", "name": "Gènes", "code": { "@type": "MedicalCode", "code": "D005796", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.340.024.340" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Gènes-suicide transgéniques", "alternateName": "Genes, Transgenic, Suicide", "url": "https://questionsmedicales.fr/mesh/D041722", "about": { "@type": "MedicalCondition", "name": "Gènes-suicide transgéniques", "code": { "@type": "MedicalCode", "code": "D041722", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G05.360.340.024.340.825.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Transgènes", "alternateName": "Transgenes", "code": { "@type": "MedicalCode", "code": "D019076", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Xia Wang", "url": "https://questionsmedicales.fr/author/Xia%20Wang", "affiliation": { "@type": "Organization", "name": "Chongqing Engineering Research Center for Floriculture, Key Laboratory of Horticulture Science for Southern Mountainous Regions of Ministry of Education, College of Horticulture and Landscape Architecture, Southwest University, Chongqing 400715, China." } }, { "@type": "Person", "name": "Taichi Oguchi", "url": "https://questionsmedicales.fr/author/Taichi%20Oguchi", "affiliation": { "@type": "Organization", "name": "Faculty of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan." } }, { "@type": "Person", "name": "Yasir Hasan Siddique", "url": "https://questionsmedicales.fr/author/Yasir%20Hasan%20Siddique", "affiliation": { "@type": "Organization", "name": "Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University , Aligarh , Uttar Pradesh , India." } }, { "@type": "Person", "name": "Falaq Naz", "url": "https://questionsmedicales.fr/author/Falaq%20Naz", "affiliation": { "@type": "Organization", "name": "Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University , Aligarh , Uttar Pradesh , India." } }, { "@type": "Person", "name": "None Rahul", "url": "https://questionsmedicales.fr/author/None%20Rahul", "affiliation": { "@type": "Organization", "name": "Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University , Aligarh , Uttar Pradesh , India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Long term study of topical interferon α-2b eye drops as primary treatment of ocular surface squamous neoplasia.", "datePublished": "2022-12-30", "url": "https://questionsmedicales.fr/article/36592780", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jtos.2022.12.009" } }, { "@type": "ScholarlyArticle", "name": "Visual outcome and ocular complications in patients with lacrimal gland carcinoma after eye-sparing surgery and adjuvant radiation therapy.", "datePublished": "2023-11-22", "url": "https://questionsmedicales.fr/article/36229179", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bjo-2022-321889" } }, { "@type": "ScholarlyArticle", "name": "Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.", "datePublished": "2022-12-05", "url": "https://questionsmedicales.fr/article/36476665", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jtos.2022.12.002" } }, { "@type": "ScholarlyArticle", "name": "A markerless beam's eye view tumor tracking algorithm based on unsupervised deformable registration learning framework of VoxelMorph in medical image with partial data.", "datePublished": "2022-12-18", "url": "https://questionsmedicales.fr/article/36535237", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejmp.2022.12.002" } }, { "@type": "ScholarlyArticle", "name": "Transitioning from a COMS-based plaque brachytherapy program to using eye physics plaques and plaque simulator treatment planning system: A single institutional experience.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36637797", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/acm2.13902" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes génétiques", "item": "https://questionsmedicales.fr/mesh/D055614" }, { "@type": "ListItem", "position": 3, "name": "Structures génétiques", "item": "https://questionsmedicales.fr/mesh/D040342" }, { "@type": "ListItem", "position": 4, "name": "Génome", "item": "https://questionsmedicales.fr/mesh/D016678" }, { "@type": "ListItem", "position": 5, "name": "Composants de génome", "item": "https://questionsmedicales.fr/mesh/D040481" }, { "@type": "ListItem", "position": 6, "name": "Gènes", "item": "https://questionsmedicales.fr/mesh/D005796" }, { "@type": "ListItem", "position": 7, "name": "Transgènes", "item": "https://questionsmedicales.fr/mesh/D019076" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Transgènes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Transgènes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Transgènes", "description": "Comment détecte-t-on des transgènes dans un organisme ?\nQuels tests sont utilisés pour analyser les transgènes ?\nLes transgènes peuvent-ils être détectés dans les aliments ?\nQuelles méthodes sont utilisées pour le diagnostic des transgènes ?\nPeut-on identifier des transgènes dans des tissus humains ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Eye+Neoplasms&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Transgènes", "description": "Quels symptômes peuvent résulter de l'expression de transgènes ?\nLes transgènes provoquent-ils des effets indésirables ?\nY a-t-il des symptômes associés aux aliments transgéniques ?\nLes transgènes peuvent-ils affecter la santé humaine ?\nQuels symptômes sont liés aux thérapies géniques ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Eye+Neoplasms&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Transgènes", "description": "Comment prévenir les risques liés aux transgènes ?\nPeut-on éviter les aliments transgéniques ?\nQuelles mesures de sécurité sont prises pour les transgènes ?\nComment sensibiliser sur les transgènes ?\nLes organismes de réglementation surveillent-ils les transgènes ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Eye+Neoplasms&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Transgènes", "description": "Comment les transgènes sont-ils utilisés en médecine ?\nLes transgènes peuvent-ils traiter des maladies ?\nQuels traitements utilisent des transgènes ?\nLes transgènes sont-ils utilisés en oncologie ?\nQuels sont les risques des traitements par transgènes ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Eye+Neoplasms&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Transgènes", "description": "Quelles complications peuvent survenir avec les transgènes ?\nLes transgènes peuvent-ils causer des maladies ?\nY a-t-il des complications environnementales liées aux transgènes ?\nComment les transgènes affectent-ils la santé publique ?\nLes transgènes peuvent-ils affecter la reproduction ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Eye+Neoplasms&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Transgènes", "description": "Quels facteurs augmentent les risques liés aux transgènes ?\nLes allergies sont-elles un facteur de risque pour les transgènes ?\nL'environnement joue-t-il un rôle dans les risques des transgènes ?\nLes antécédents médicaux influencent-ils les risques liés aux transgènes ?\nL'âge est-il un facteur de risque pour les effets des transgènes ?", "url": "https://questionsmedicales.fr/mesh/D019076?mesh_terms=Eye+Neoplasms&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on des transgènes dans un organisme ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des techniques comme la PCR et le séquençage pour identifier les transgènes." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour analyser les transgènes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'analyse de l'ADN par électrophorèse et la hybridation." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils être détectés dans les aliments ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests spécifiques peuvent identifier la présence de transgènes dans les aliments." } }, { "@type": "Question", "name": "Quelles méthodes sont utilisées pour le diagnostic des transgènes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent la PCR quantitative et les tests de Southern blot." } }, { "@type": "Question", "name": "Peut-on identifier des transgènes dans des tissus humains ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques comme la PCR peuvent détecter des transgènes dans des échantillons de tissus." } }, { "@type": "Question", "name": "Quels symptômes peuvent résulter de l'expression de transgènes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon le transgène, mais peuvent inclure des réactions immunitaires." } }, { "@type": "Question", "name": "Les transgènes provoquent-ils des effets indésirables ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets indésirables peuvent survenir, comme des allergies ou des toxicités." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés aux aliments transgéniques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines personnes peuvent éprouver des symptômes allergiques après consommation." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils affecter la santé humaine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que certains transgènes peuvent avoir des impacts sur la santé." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux thérapies géniques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies géniques peuvent entraîner des réactions comme de la fièvre ou des douleurs." } }, { "@type": "Question", "name": "Comment prévenir les risques liés aux transgènes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La réglementation stricte et les tests de sécurité sont essentiels pour prévenir les risques." } }, { "@type": "Question", "name": "Peut-on éviter les aliments transgéniques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en choisissant des produits bio ou en lisant les étiquettes des aliments." } }, { "@type": "Question", "name": "Quelles mesures de sécurité sont prises pour les transgènes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des études de sécurité et des évaluations environnementales sont réalisées avant leur utilisation." } }, { "@type": "Question", "name": "Comment sensibiliser sur les transgènes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des campagnes d'information et des programmes éducatifs peuvent sensibiliser le public." } }, { "@type": "Question", "name": "Les organismes de réglementation surveillent-ils les transgènes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des organismes comme l'EFSA surveillent l'utilisation et la sécurité des transgènes." } }, { "@type": "Question", "name": "Comment les transgènes sont-ils utilisés en médecine ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont utilisés pour développer des thérapies géniques pour traiter des maladies génétiques." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils traiter des maladies ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les transgènes sont utilisés pour traiter des maladies comme la fibrose kystique." } }, { "@type": "Question", "name": "Quels traitements utilisent des transgènes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements comme la thérapie génique et les vaccins génétiquement modifiés en font partie." } }, { "@type": "Question", "name": "Les transgènes sont-ils utilisés en oncologie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont utilisés pour développer des traitements ciblés contre certains cancers." } }, { "@type": "Question", "name": "Quels sont les risques des traitements par transgènes ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des réactions immunitaires et des effets secondaires imprévus." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les transgènes ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des réactions allergiques et des effets à long terme non prévus." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils causer des maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Il existe des préoccupations sur le potentiel des transgènes à induire des maladies." } }, { "@type": "Question", "name": "Y a-t-il des complications environnementales liées aux transgènes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des impacts sur la biodiversité et des effets sur les écosystèmes sont possibles." } }, { "@type": "Question", "name": "Comment les transgènes affectent-ils la santé publique ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent poser des risques pour la santé publique, nécessitant une surveillance continue." } }, { "@type": "Question", "name": "Les transgènes peuvent-ils affecter la reproduction ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que certains transgènes pourraient avoir des effets sur la reproduction." } }, { "@type": "Question", "name": "Quels facteurs augmentent les risques liés aux transgènes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'exposition à des transgènes non réglementés et la consommation d'aliments non testés augmentent les risques." } }, { "@type": "Question", "name": "Les allergies sont-elles un facteur de risque pour les transgènes ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes allergiques peuvent avoir des réactions plus sévères aux aliments transgéniques." } }, { "@type": "Question", "name": "L'environnement joue-t-il un rôle dans les risques des transgènes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les conditions environnementales peuvent influencer l'impact des transgènes sur la santé." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils les risques liés aux transgènes ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies auto-immunes peuvent augmenter les risques." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour les effets des transgènes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées peuvent être plus sensibles aux effets des transgènes." } } ] } ] }

Sources (9854 au total)

Long term study of topical interferon α-2b eye drops as primary treatment of ocular surface squamous neoplasia.

To assess the efficacy of topical interferon α-2β(IFN) eye drops as a primary treatment for ocular surface squamous neoplasia(OSSN) and evaluate factors that impact response to treatment and recurrenc... A retrospective study of 143 OSSN patients treated with topical IFN(1MIU/ml) from January 1998 to June 2021. The diagnosis was based on clinical examination and anterior segment optical coherence tomo... Participants were mostly older (mean age, 69 years, SD 12.9, range 29-97), white(89%) males (74%). Complete tumor resolution was achieved in 80.4% of individuals with a mean time to resolution of 4.2 ... Topical IFN eye drops are a safe and effective primary treatment modality for OSSN with a reasonable side effect profile....

Visual outcome and ocular complications in patients with lacrimal gland carcinoma after eye-sparing surgery and adjuvant radiation therapy.

We report visual outcomes and ocular complications in patients with lacrimal gland carcinoma who had eye-sparing surgery followed by radiotherapy.... This review included consecutive patients with lacrimal gland carcinoma who underwent eye-sparing surgery and adjuvant radiotherapy or concurrent chemoradiation therapy between 2007 and 2018. Clinical... The study included 23 patients, 15 males and 8 females, with median age 51 years. Twenty patients (87%) received intensity-modulated proton therapy; 3 (13%) received intensity-modulated radiotherapy. ... Eye-sparing surgery followed by adjuvant radiotherapy in patients with lacrimal gland carcinoma has a reasonable overall visual prognosis. Patients with tumours crossing the orbital midline and Hispan...

Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study.

To determine the efficacy and safety of topical 1% 5-fluorouracil (5FU) eye drops as primary treatment of ocular surface squamous neoplasia (OSSN).... Patients were diagnosed with OSSN based on slit-lamp examination and anterior segment optical coherence tomography (AS-OCT). In ambiguous cases an incisional biopsy was performed. All were treated wit... The mean age of 251 subjects (258 eyes) was 67.5 ± 11.7 years, 182 were male. Patients were followed up on average for 752 ± 580 days. Overall, 87% of patients experienced complete tumor resolution. M... Topical 1% 5FU eye drops are a safe and effective medication for OSSN. Superior tumor location and leukoplakia decreased the chance of tumor resolution....

A markerless beam's eye view tumor tracking algorithm based on unsupervised deformable registration learning framework of VoxelMorph in medical image with partial data.

To propose an unsupervised deformable registration learning framework-based markerless beam's eye view (BEV) tumor tracking algorithm for the inferior quality megavolt (MV) images with occlusion and d... Quality assurance (QA) plans for thorax phantom were delivered to the linear accelerator with artificially treatment offsets. Electronic portal imaging device (EPID) images (682 in total) and correspo... The tracking algorithm can handle image registration with non-rigid deformation and losses ranging from 10 % to 80 %. The tracking errors in the phantom study were below 3 mm in about 86.8 % of cases,... The study provides a robust markerless tumor tracking algorithm for multi-modal, partial data and inferior quality image processing....

Transitioning from a COMS-based plaque brachytherapy program to using eye physics plaques and plaque simulator treatment planning system: A single institutional experience.

The aim of this work is to describe the implementation and commissioning of a plaque brachytherapy program using Eye Physics eye plaques and Plaque Simulator treatment planning system based on the exp...

[Severe Conjunctival and Corneal Epithelial Dysplasia: A Case Series].

Ocular surface squamous neoplasia (OSSN) are among the most frequent non-pigmented malignancies of the ocular surface. They have a wide range of histological characteristics - ranging from mild epithe... Retrospective case series of patients with histologically confirmed severe epithelial dysplasia of the conjunctiva and cornea consistent with OSSN who presented to the Department of Ophthalmology in B... We report on five patients aged between 41 and 92 years at the time of diagnosis. The histological findings in all patients included severe epithelial dysplasia, but with a heterogenous clinical prese... The clinical presentation of OSSN is highly heterogenous, so that the initial diagnosis is difficult. There are no official guidelines for treatment, so that the treatment of choice varied between cli...

Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.

Ocular surface squamous neoplasia (OSSN) comprises a wide spectrum of squamous tumors, from which corneal/conjunctival intraepithelial neoplasia (CIN) is the most common one. The classic treatment is ... Patients diagnosed with localized CIN were evaluated by slit lamp and impression cytology and were randomly given MMC 0.04% or INF2b (1 million IU/mL) 4 times daily until neoplasia resolution. Time of... Seventeen patients were included. Nine patients were treated with MMC and 8 with IFNα2b. All patients responded to treatment. The resolution time in days was 59.11 ± 24.02 in patients treated with MMC... Topical chemotherapy with MMC and IFNα2b demonstrate pharmacological safety and efficacy. Therefore, these drugs could be considered as primary therapies for localized CIN ....